Australia-wide dispatch

Quantified
Peptides
PE-22-28 10mg — research peptide, lyophilised powder in a glass vial, supplied by Quantified Peptides, Sydney, Australia. For in-vitro research use only.

Peptides

PE-22-28

PE-22-28 (Spadin analogue), spadin analogue — NTSR3/sortilin propeptide. Supplied as a lyophilised powder in 10mg vials.

Supplied as lyophilised powder in a 10mg specification. Storage: -20°C · Keep dry, avoid light. Dispatched from Sydney, Australia-wide.

Product information

About PE-22-28

PE-22-28 (Spadin analogue)

Research background as published in the scientific literature. Supplied for in-vitro laboratory research only; nothing here is a claim about use in humans or animals.

PE-22-28 is a synthetic peptide derived from the propeptide of NTSR3/sortilin and is an optimised analogue of Spadin, a natural TREK-1 antagonist. TREK-1 is a two-pore domain (K2P) potassium channel expressed in neurons that regulates resting membrane potential.

Research interest in TREK-1 antagonists increased when TREK-1 knockout mice showed antidepressant-like phenotypes. PE-22-28 was developed as an improved Spadin analogue with enhanced stability and potency, and has been studied in preclinical antidepressant models for its effects on serotonin neurotransmission and behavioural outcomes.

Type
Synthetic TREK-1 antagonist peptide
Research Areas
Antidepressant mechanisms, TREK-1 channel modulation
Origin
Spadin analogue — NTSR3/sortilin propeptide
Target
TREK-1 (KCNK2) K2P potassium channel
Molecular Weight
~800 Da
Research Area
Antidepressant mechanisms
Animal Models
FST, TST — rapid onset
Key Pathway
TREK-1 → serotonin system
  1. 01TREK-1 Potassium Channel AntagonismPE-22-28 is a synthetic optimised analogue of Spadin that acts as an antagonist of the TREK-1 (KCNK2) two-pore domain potassium channel. Research has examined how TREK-1 blockade modulates neuronal excitability and serotonergic transmission.
  2. 02Serotonin System ModulationResearch has investigated PE-22-28's effects on serotonergic neurotransmission, with studies examining whether TREK-1 antagonism increases serotonin availability in relevant brain regions through enhanced neuronal firing rates.
  3. 03Rapid-Onset ResearchA key research interest in TREK-1 antagonists is their potential for rapid-onset antidepressant-like effects in preclinical models. Research has examined PE-22-28 in forced swim test and tail suspension models, with studies reporting faster onset than monoamine-based comparators.

References

  1. 1Mazella J et al. Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels. Mol Psychiatry. 2010;15(12):1163-1169.
  2. 2Moha Ou Maati H et al. Protein- and acid-sensing ion channel 1a are targets for the antidepressant peptide Spadin. Antioxid Redox Signal. 2012.
  3. 3PubMed: pubmed.ncbi.nlm.nih.gov/?term=PE-22-28+TREK-1
  4. 4Djillani A et al. Antidepressant effects of a new series of TREK-1 inhibitors. Br J Pharmacol. 2019;176(22):4460-4475.

Ships from Sydney

Australia-wide, plain unbranded packaging. Dispatched on business days.

If it arrives wrong

Replaced, resent or refunded. You do not have to argue for it.

Also in this range.

Compounds the supplier files alongside this one.

View the range